Gia Nemsadze

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Peter Schmid, Jacinta Abraham, Stephen Chan et al. · Journal of Clinical Oncology · 2019 · 373 citations · Full text

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

Hope S. Rugo, Abhijit Barve, Cornelius F. Waller et al. · JAMA · 2016 · 142 citations · Full text

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

Peter Schmid, Catherine Harper‐Wynne, M. Ferreira et al. · JAMA Oncology · 2019 · 90 citations · Full text

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Brian Leyland‐Jones, Igor Bondarenko, Gia Nemsadze et al. · Journal of Clinical Oncology · 2016 · 66 citations

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Peter Schmid, Jacinta Abraham, Stephen Chan et al. · Journal of Clinical Oncology · 2018 · 61 citations

First-line Therapy, Breast Oncology, Pathology +16